Boehringer Ingelheim’s sales of chronic obstructive pulmonary disease drugs may be flagging, but they still remain substantial and require millions of inhalers to deliver them. To provide for that, the company has opened a new inhaler plant in Spain soon after adding production lines to plants in Germany, expansions that bring its recent investments in the Respimat inhaler to about €225 million
Olodaterol - List of nationally authorised medicinal products
RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & olodaterol) Inhalation Spray that includes data showing a meaningful reduction in COPD exacerbations driven by tiotropium, which is the active ingredient in Spiriva Respimat (tiotropium bromide) Inhalation Spray. Stiolto Respimat is a combination medicine that includes tiotropium.
RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & olodaterol) Inhalation Spray that includes data showing a meaningful reduction in COPD exacerbations driven by tiotropium, which is the active ingredient in Spiriva Respimat (tiotropium bromide) Inhalation Spray. Stiolto Respimat is a combination medicine that includes tiotropium.
RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & olodaterol) Inhalation Spray that includes data showing a meaningful reduction in COPD exacerbations driven by tiotropium, which is the active ingredient in Spiriva Respimat (tiotropium bromide) Inhalation Spray. Stiolto Respimat is a combination medicine that includes tiotropium.
Boehringer Ingelheim announced results from the OTIVACTO study, an observational European real-world study of 7,443 Chronic Obstructive Pulmonary Disease (COPD) patients treated with Spiolto® (tiotropium/olodaterol) Respimat®, which were presented today at the European Respiratory Society (ERS) International Congress 2018 in Paris, France. Patients in the study reported both improved physical functioning and general condition and high satisfaction with their inhalation device and treatment overall. The improvements were observed in patients across disease severities.
Boehringer Ingelheim today announced the first results from the Phase IIIb/IV PHYSACTO trial that showed STIOLTO RESPIMAT, combined with exercise training, helps people with COPD walk for longer periods of time compared to those receiving placebo. All participants of the trial were also enrolled in a self-management behavior modification program, which provided health education and skills to help better manage COPD. These data were presented today at the European Respiratory Society (ERS) International Congress 2016 in London.
When Boehringer Ingelheim's COPD drug Stiolto Respimat won U.S. approval early last month, the company's head of pharma marketing and sales, Allan Hillgrove, acknowledged that payer arm-twisting happening stateside may make pricing tough. But now, the German drugmaker has nabbed some European approvals that should give the drug a lift.
Boehringer`s Stiolto Respimat (Tiotropium Bromide;Olodaterol) Approved in US For COPD